JPRN-C000000168已完成1 期
Phase I study of non-myeloablative conditioning regimen of Fludarabine/melphalan for hematopoietic stemcell transplantation from HLA matched sibling donors in patient with multiple myeloma that refractory or relapsed for autologous stem cell transplantation (C-SHOT0403) - Phase I study of non-myeloablative conditioning regimen of Fludarabine/melphalan for hematopoietic stemcell transplantation from HLA matched sibling donors in patient with multiple myeloma that refractory or relapsed for autologous stem cell transplantation (C-SHOT0403)
agoya BMT Group0 个研究点目标入组 12 人开始时间: 2005年9月12日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 65years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Insulin dependent diabetes mellitus 2) Uncontrolable HT 3) Unstable angina, heart failure, or myocardial infarction 4) interstitial pneumonia or pulmonary fibrosis 5) positive HBs antigen 6) seropositive to HCV 7) seropositive to HIV 8) Severe infections 9)double cancer 10)Pregnant women 11) Sever mental disease 12) Patients inappropriate for transplantation with reasons other than above.
研究者
相似试验
招募中
2 期
Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling DonorStem Cell Transplant ComplicationsRed Blood Cell DisorderSickle Cell DiseasePure Red Cell AplasiaNCT03214354University of Calgary12
进行中（未招募）
1 期
onmyeloablative Conditioning with Pre- and Post-Transplant Rituximab followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients with Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial - FHCRC protocol 1840 for CChronic lymphocytic leukemia (CLL) is a malignant disease. CLL is the most common form of leukemia in western countries. Median age at diagnosis is 70 years, and only 10-15% of patients are younger than 50 years. Despite some therapeutic progress, standard treatment is not curative for CLLMedDRA version: 12.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaEUCTR2009-015968-34-DKFRED HUTCHINSON CANCER RESEARCH CENTER80
进行中（未招募）
不适用
onmyeloablative Conditioning with Pre- and Post-Transplant Rituximab followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients with Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial - NDEUCTR2009-017449-72-ITFRED HUTCHINSON CANCER RESEARCH CENTER UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE SEATTLE CHILDRE40
终止
1 期
Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell DiseaseSickle Cell DiseaseNCT02678143Washington University School of Medicine1
进行中（未招募）
1 期
Randomized Phase II Study Using a Non-myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of Tumor Infiltrating Lymphocytes and Interleukin-2 in Metastatic Melanoma’ - Lymphodepletion, TIL and Interleukin 2Patients with metastatic (stage IV) melanoma will be randomized to either treatment arm A (dacarbazine) or treatment arm B (TIL) after metastasectomy and feasibility of culturing of TIL.MedDRA version: 12.1Level: LLTClassification code 10053571Term: MelanomaEUCTR2010-021885-31-NLKI-AV